A gene therapy success in Huntington’s and Trump’s autism announcement
Why were doctors and investors so excited about trial results of UniQure’s gene therapy for Huntington’s disease? Are autism rates actually rising? And what does the research tell us about Tylenol and autism?
We discuss all that on this week’s episode of the “The Readout LOUD,” STAT’s biotech podcast. We bring on UniQure CEO Matt Kapusta to discuss the company’s announcement this week that its one-time treatment for Huntington’s disease significantly slowed down the neurological condition in a key study.
Elaine Chen, Adam Feuerstein, and Allison DeAngelis
Go to statnews